Alyra Therapeutics, Inc.
Research - Encinitas, California, United States
Alyra Therapeutics, Inc. Employees
Alyra Therapeutics, Inc. Details
Founded in 2020 and headquartered in San Diego, California, Alyra Therapeutics is developing proprietary protein-protein interaction drugs that block the binding of ras oncogene small GTPases to their effectors. Our focus is on the CDC42 family of GTPases, specifically the CDC42 and RHOJ proteins. Using a platform comprising proprietary molecular dynamics methods coupled with protein-protein interaction assay workflows, Alyra has developed several classes of compounds that selectively block the interactions between these GTPases and a key effector, p21 activated kinase 1 (PAK1), without blocking the interactions between GTPases such as RAL and RAC1 and their effectors. Our lead clinical candidate is ALY101, a PAK1 inhibitor which binds to a common motif on the CDC42 and RHOJ GTPases, preventing their ability to bind to and activate PAK1 and its downstream targets, including the MEK and ERK kinases. ALY101 shows significant potential as an adjunctive therapy used in conjunction with targeted therapies and immune-oncology drugs to expand the therapeutic indices of these drugs, increasing safety, efficacy and patient compliance, especially for products with serious safety and tolerability issues that limit their use.
Alyra Therapeutics, Inc. Technologies
Email Providers
Outlook
Hosting
GoDaddy Hosting
Other
Mobile Friendly